Human Plasma Proteins

© 2008 Elsevier. All rights reserved. The pentavalent Tc-99m dimercaptosuccinic acid (Tc99m (V) DMSA, Tc(V)-DMSA) radiotracer has become more widely used. The accumulation of Tc(V)-DMSA in tumors was first reported in 1981 [1], and this tracer has subsequently been shown to localize in a variety of tumors [2,3]. Tc(V)-DMSA has also been used to depict abscesses and other inflammatory lesions [4–6]. Compared with conventional inflammation and the tumor-imaging agent Ga-67 citrate (Ga-citrate), Tc(V)-DMSA has superior characteristics, such as better physical properties, lower cost, and less time delay between radiotracer injection and imaging. In addition, compared with some recently developed radiopharmaceuticals for oncologic imaging, such as monoclonal antibodies, metabolic substrates and receptor-avid peptides, Tc(V)-DMSA remains costeffective, widely available and clinically accepted. Despite years of experience with Tc(V)-DMSA imaging, the precise mechanism by which Tc(V)-DMSA Received: May 2, 2007 Accepted: Oct 14, 2007 Address correspondence and reprint requests to: Dr Bi-Fang Lee, Department of Nuclear Medicine, National Cheng Kung University Hospital, 138 Sheng-Li Road, Tainan 704, Taiwan. E-mail: [email protected] EVALUATION OF TC-99M (V) DMSA BINDING TO HUMAN PLASMA PROTEINS